What's Going On With Johnson & Johnson Stock Friday?
I'm PortAI, I can summarize articles.
Nipocalimab combo therapy showed no added efficacy over anti-TNFα treatment in the Phase 2a trial. Johnson & Johnson ended the RA study but sees over $5 billion in potential for nipocalimab. Get a Year of Fast, Actionable Trade Alerts for 60% Off This Labor Day
Source: Benzinga The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments